| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Hubei Biocause Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥1.85 |
| 52 Week High | CN¥3.91 |
| 52 Week Low | CN¥1.82 |
| Beta | 0.40 |
| 11 Month Change | -23.87% |
| 3 Month Change | -27.45% |
| 1 Year Change | -38.13% |
| 33 Year Change | -49.73% |
| 5 Year Change | -71.49% |
| Change since IPO | -77.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 627 | CN Insurance | CN Market | |
|---|---|---|---|
| 7D | -1.6% | 1.6% | -1.6% |
| 1Y | -38.1% | 10.4% | -15.7% |
Return vs Industry: 000627 underperformed the CN Insurance industry which returned 10.4% over the past year.
Return vs Market: 000627 underperformed the CN Market which returned -15.7% over the past year.
Price Volatility
| 627 volatility | |
|---|---|
| 627 Average Weekly Movement | 5.5% |
| Insurance Industry Average Movement | 5.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 000627's share price has been volatile over the past 3 months.
Volatility Over Time: 000627's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1,765 | Wenxia Zhou | www.biocause.com |
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride.
Hubei Biocause Pharmaceutical Co., Ltd. Fundamentals Summary
| 627 fundamental statistics | |
|---|---|
| Market cap | CN¥9.14b |
| Earnings (TTM) | -CN¥786.84m |
| Revenue (TTM) | CN¥43.81b |
0.2x
P/S Ratio-11.6x
P/E RatioIs 627 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 627 income statement (TTM) | |
|---|---|
| Revenue | CN¥43.81b |
| Cost of Revenue | CN¥40.86b |
| Gross Profit | CN¥2.95b |
| Other Expenses | CN¥3.74b |
| Earnings | -CN¥786.84m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 6.74% |
| Net Profit Margin | -1.80% |
| Debt/Equity Ratio | 70.9% |
How did 627 perform over the long term?
See historical performance and comparison